產(chǎn)品編號(hào) | bs-1100R |
英文名稱 | Rabbit Anti-CD36 antibody |
中文名稱 | CD36抗體 |
別 名 | Platelet glycoprotein 4; PAS-4; Platelet glycoprotein IV; Glycoprotein IIIb; GPIV; GPIIIB; GP3B; Leukocyte differentiation antigen CD36; PAS IV; Platelet collagen receptor; Fatty acid translocase; FAT; Thrombospondin receptor; CD_antigen: GP4; CD36_HUMAN. |
Specific References (4) | bs-1100R has been referenced in 4 publications.
[IF=4.109] Yu Haiyi. et al. The Foam Cell Formation Associated With Imbalanced Cholesterol Homeostasis Due to Airborne Magnetite Nanoparticles Exposure. TOXICOL SCI. 2022 Aug;: WB ; Mouse, Human.
[IF=3.974] Astragaloside IV inhibits palmitate-mediated oxidative stress and fibrosis in human glomerular mesangial cells via downregulation of CD36 expression
Y Su WB ; Rat &Human.
[IF=2.752] Jie Song. et al. Ethanol Extract of Artemisia Annua Prevents LPS-Induced Inflammation and Blood–Milk Barrier Disruption in Bovine Mammary Epithelial Cells. ANIMALS. 2022 Jan;12(10):1228 WB ; Bovine.
[IF=0] Afolabi Oladele Ayobami. et al. Diet-induced insulin resistance altered cardiac GLUT4 and FATP/CD36 expression in rats. Beni-Suef University Journal of Basic and Applied Sciences. 2022 Dec;11(1):1-8 IHC ; Rat.
|
|
研究領(lǐng)域 | 腫瘤 心血管 細(xì)胞生物 免疫學(xué) 干細(xì)胞 細(xì)胞膜受體 細(xì)胞類型標(biāo)志物 血管內(nèi)皮細(xì)胞 內(nèi)皮細(xì)胞 |
抗體來源 | Rabbit |
克隆類型 | Polyclonal |
交叉反應(yīng) | Human,Mouse,Rat |
產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
理論分子量 | 52kDa |
檢測分子量 | 85-90 |
細(xì)胞定位 | 細(xì)胞膜 |
性 狀 | Liquid |
濃 度 | 1mg/ml |
免 疫 原 | KLH conjugated synthetic peptide derived from human CD36: 301-400/472 <Extracellular> |
亞 型 | IgG |
純化方法 | affinity purified by Protein A |
緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
PubMed | PubMed |
產(chǎn)品介紹 |
The protein encoded by this gene is the fourth major glycoprotein of the platelet surface and serves as a receptor for thrombospondin in platelets and various cell lines. Since thrombospondins are widely distributed proteins involved in a variety of adhesive processes, this protein may have important functions as a cell adhesion molecule. It binds to collagen, thrombospondin, anionic phospholipids and oxidized LDL. It directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes and it binds long chain fatty acids and may function in the transport and/or as a regulator of fatty acid transport. Mutations in this gene cause platelet glycoprotein deficiency. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Feb 2014] Function: Seems to have numerous potential physiological functions. Binds to collagen, thrombospondin, anionic phospholipids and oxidized LDL. May function as a cell adhesion molecule. Directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Binds long chain fatty acids and may function in the transport and/or as a regulator of fatty acid transport. Receptor for thombospondins, THBS1 AND THBS2, mediating their antiangiogenic effects. Subunit: Interacts with THBS1 and THBS2; the interactions mediate the THBS antiangiogenic activity. Subcellular Location: Membrane; Multi-pass membrane protein. Tissue Specificity: Predominant in heart, intestine, spleen, fat, skeletal muscle, lower in testes. Post-translational modifications: N-glycosylated and O-glycosylated with a ratio of 2:1. DISEASE: Defects in CD36 are the cause of platelet glycoprotein IV deficiency (PG4D)[MIM:608404]; also known as CD36 deficiency. Platelet glycoprotein IV deficiency can be divided into 2 subgroups. The type I phenotype is characterized by platelets and monocytes/macrophages exhibiting complete CD36 deficiency. The type II phenotype lacks the surface expression of CD36 in platelets, but expression in monocytes/macrophages is near normal. Genetic variations in CD36 are associated with susceptibility to coronary heart disease type 7 (CHDS7) [MIM:610938]. Similarity: Belongs to the CD36 family. SWISS: Q08857 Gene ID: 12491 Database links: Entrez Gene: 948 Human Entrez Gene: 12491 Mouse Omim: 173510 Human SwissProt: P16671 Human SwissProt: Q08857 Mouse Unigene: 120949 Human Unigene: 18628 Mouse Unigene: 406799 Mouse Unigene: 102418 Rat Unigene: 205840 Rat
CD36屬一種多功能細(xì)胞膜受體,CD36參與長鏈脂肪酸的吸附和調(diào)節(jié)細(xì)胞凋亡殘物的清理和巨噬細(xì)胞的吞噬作用, 屬于一種抗蛋白酶血小板膜表面糖蛋白。 CD36 廣泛在單核細(xì)胞、巨噬細(xì)胞、內(nèi)皮層細(xì)胞、血小板、紅細(xì)胞前板、脂肪細(xì)胞、肌肉細(xì)胞以及乳腺內(nèi)皮層細(xì)胞中有不同的表達(dá)。CD36抗原是血小板反應(yīng)素的配體,兩者結(jié)合后產(chǎn)生抑制腫瘤血管生成的效應(yīng)。 |
產(chǎn)品圖片 |
Sample:
Lane 1: Mouse Placenta tissue lysates
Lane 2: Mouse Raw264.7 cell lysates
Lane 3: Rat Placenta tissue lysates
Lane 4: Human HUVEC cell lysates
Lane 5: Human HL-60 cell lysates
Primary: Anti-CD36 (bs-1100R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 52 kDa
Observed band size: 100 kDa
Sample:
Lane 1: Human HepG2 cell lysates
Lane 2: Human HUVEC cell lysates
Lane 3: Human MCF-7cell lysates
Primary: Anti-CD36 (bs-1100R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 52 kDa
Observed band size: 90 kDa
Sample:
Lane 1: Mouse Kidney tissue lysates
Lane 2: Mouse Raw264.7 cell lysates
Primary: Anti-CD36 (bs-1100R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 52 kDa
Observed band size: 100 kDa
Tissue/cell: rat heart tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-CD36/PAS-4 Polyclonal Antibody, Unconjugated(bs-1100R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|